Data as of Sep 17
| -0.04 / -0.22%|
The 6 analysts offering 12-month price forecasts for Theravance Inc have a median target of 27.50, with a high estimate of 47.00 and a low estimate of 7.00. The median estimate represents a +49.38% increase from the last price of 18.41.
The current consensus among 7 polled investment analysts is to Hold stock in Theravance Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.